Investment
Features
FeesSafety
Academy
More
Pluang+

F.N.B. reports Q3 2026 net income of $152.9M, driven by record net interest income and strong loan growth.

Company Fundamentals
19 Oct 2026
PRNewsWire
View Source
Bullish
F.N.B. reports Q3 2026 net income of $152.9M, driven by record net interest income and strong loan growth.

F.N.B. Corporation posted a net income of $152.9 million in Q3 2026, up from $149.5 million in Q3 2025, supported by record net interest income and expanded net interest margin. The bank saw 8.5% annualized loan growth and 8.9% deposit growth, reflecting strong organic expansion and solid credit quality. Tangible book value per share rose 7% year-over-year, while the company continued share repurchases and dividends. These results highlight F.N.B.'s strategic investments in technology and diversified revenue streams, positioning it for sustainable future growth.

F.N.B. Corporation's Q3 2026 earnings provide context for financial sector performance. For readers following Financials, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 142 priced US Financials stocks, 42 rose and 99 fell. Notable movers include Lemonade Inc (LMND) at USD 46.03 with a 1-day change of +4.95%, W.R. Berkley Corporation (WRB) at USD 71.86 down -4.72%, and Global Payments Inc (GPN) at USD 84.48 with 100% buy order activity and a typical hold time of 50 days on Pluang.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
30 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
30 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App